23andMe, a consumer genetics and research company, agreed to acquire Lemonaid Health, an leading innovator in telemedicine and prescription drug delivery, for $400m. "We believe that by combining Lemonaid Health’s telemedicine platform, including its online team of medical professionals and its pharmacy services, with our consumer business, we are taking an important step in transforming the traditional primary care experience and making personalized healthcare a reality. By starting with genetics as the foundation, we will give patients and healthcare providers better information about health risks and treatments, opening up the door to prevent as well as better manage disease. Lemonaid Health’s focus on the patient and its philosophy of delivering individualized care fits perfectly with our mission of empowering people to take control of their health," Anne Wojcicki, 23andMe CEO and Co-Founder.